BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 17378122)

  • 1. [Prognostic significance of Sphase fraction in ovarian cancer patients].
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Debniak J
    Ginekol Pol; 2006 Nov; 77(11):840-7. PubMed ID: 17378122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [DNA ploidy and results of first line chemotherapy in ovarian cancer patients].
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Debniak J
    Ginekol Pol; 2006 Aug; 77(8):589-96. PubMed ID: 17076189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
    Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
    Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry.
    Reles AE; Gee C; Schellschmidt I; Schmider A; Unger M; Friedmann W; Lichtenegger W; Press MF
    Gynecol Oncol; 1998 Oct; 71(1):3-13. PubMed ID: 9784312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome.
    Demirel D; Laucirica R; Fishman A; Owens RG; Grey MM; Kaplan AL; Ramzy I
    Cancer; 1996 Apr; 77(8):1494-500. PubMed ID: 8608534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma.
    Kaern J; Tropé CG; Kristensen GB; Pettersen EO
    Cancer; 1994 Apr; 73(7):1870-7. PubMed ID: 8137213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
    Meyer JS; Gersell DJ; Yim S
    Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of DNA quantification by flow cytometry in ovarian tumors.
    Kim YT; Zhao M; Kim SH; Lee CS; Kim JH; Kim JW
    Int J Gynaecol Obstet; 2005 Mar; 88(3):286-91. PubMed ID: 15733883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome.
    Huuhtanen RL; Blomqvist CP; Wiklund TA; Virolainen MJ; Elomaa AI; Pan Y; Tribukait B
    Cancer; 1996 May; 77(9):1815-22. PubMed ID: 8646679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
    Pinto AE; André S; Pereira T; Silva G; Soares J
    Pathobiology; 2006; 73(2):63-70. PubMed ID: 16943686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary.
    Bakshi N; Rajwanshi A; Patel F; Ganguly NK
    Anal Quant Cytol Histol; 1998 Jun; 20(3):215-20. PubMed ID: 9642449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferating cell nuclear antigen (PCNA) and Ki-67 in epithelial ovarian tumours: correlation with DNA flow cytometric analysis.
    Karaburun S; Karaveli S; Peştereli HE; Simsek T; Sargin CF
    Adv Clin Path; 2001 Jan; 5(1-2):3-9. PubMed ID: 11753828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometry in primary breast carcinomas: prognostic impact of S-phase fraction according to different analysis patterns.
    Michels JJ; Marnay J; Plancoulaine B; Chasle J
    Cytometry B Clin Cytom; 2004 May; 59(1):32-9. PubMed ID: 15108168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of DNA flow cytometry in the locally recurrent, conservatively treated breast cancer patient.
    Haffty BG; Toth M; Flynn S; Fischer D; Carter D
    J Clin Oncol; 1992 Dec; 10(12):1839-47. PubMed ID: 1453198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.
    Alderisio M; Cenci M; Valli C; Russo A; Bazan V; Dardanoni G; Cucciarre S; Carreca I; Macaluso MP; Tomasino RM; Vecchione A
    Anticancer Res; 1998; 18(6A):4225-30. PubMed ID: 9891471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major salivary gland lesions: correlation of MR findings with flow cytometric DNA analysis and prognosis.
    Takashima S; Sone S; Horii A; Okamoto S; Yoshida J
    AJR Am J Roentgenol; 1996 Nov; 167(5):1297-304. PubMed ID: 8911200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
    Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
    Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of DNA ploidy pattern, S-phase fraction (SPF), and proliferating cell nuclear antigen (PCNA) in patients with primary gastric lymphoma.
    Belessi CJ; Parasi AS; Manioudaki HS; Laoutaris NP; Legakis NC; Peros GT; Androulakis GA
    J Surg Oncol; 2003 Apr; 82(4):247-55. PubMed ID: 12672009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.